Monlunabant (INV-202, MRI-1891, or S-MRI-1891) is a peripherally selective

cannabinoid receptor 1 Cannabinoid receptor 1 (CB1), is a G protein-coupled cannabinoid receptor that in humans is encoded by the ''CNR1'' gene. And discovered, by determination and characterization in 1988, and cloned in 1990 for the first time. The human CB1 recep ...

inverse agonist In pharmacology, an inverse agonist is a drug that binds to the same receptor as an agonist but induces a pharmacological response opposite to that of the agonist. A neutral antagonist has no activity in the absence of an agonist or inverse agon ...

, discovered as a β-arrestin-2-biased cannabinoid receptor 1 antagonist by Dr George Kunos, Dr Resat Cinar, and Dr Malliga Iyer at the

National Institutes of Health The National Institutes of Health (NIH) is the primary agency of the United States government responsible for biomedical and public health research. It was founded in 1887 and is part of the United States Department of Health and Human Service ...

. It was developed as a

weight loss drug Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body, weight regulation, by: reducing appetite and con ...

by Inversago Pharma. Novo Nordisk’s obesity drug monlunabant showed only modest weight loss in a Phase 2a trial. The drug was associated with higher rates of mild to moderate neuropsychiatric side effects like anxiety and sleep disturbances. Suicidal ideations were not reported.

References

{{Cannabinoid receptor modulators CB1 receptor antagonists Experimental anti-obesity drugs Peripherally selective drugs Pyrazolines 4-Chlorophenyl compounds Trifluoromethyl compounds Acylguanidines

See also

References